Amyloid light chain (AL) amyloidosis is among the more common and more severe of the
amyloidoses usually involving the slow proliferation of a bone-marrow-residing plasma cell …

Background Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by
deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells …

Immunoglobulin light chain amyloidosis (AL) commonly presents with nephrotic range
proteinuria, heart failure with preserved ejection fraction, nondiabetic peripheral neuropathy …

Although no therapies are approved for light chain (AL) amyloidosis, cyclophosphamide,
bortezomib, and dexamethasone (CyBorD) is considered standard of care. Based on …

Daratumumab, a monoclonal CD38 antibody, is approved in the treatment of myeloma, but
its efficacy and safety in light-chain (AL) amyloidosis has not been formally studied. This …

Daratumumab is a human monoclonal antibody targeting CD38, an antigen uniformly
expressed by plasma cells in multiple myeloma and light-chain amyloidosis (AL). We report …

Venetoclax is efficacious in relapsed/refractory t (11; 14) multiple myeloma, thus warranting
investigation in light-chain amyloidosis (AL). This retrospective cohort includes 43 patients …

Aims Concomitant cardiac amyloidosis (CA) in severe aortic stenosis (AS) is difficult to
recognize, since both conditions are associated with concentric left ventricular thickening …

Disease overview Immunoglobulin light chain amyloidosis is a clonal, nonproliferative
plasma cell disorder in which fragments of immunoglobulin light or heavy chain are …

Systemic light-chain (AL) amyloidosis is caused by a small B cell, most commonly a plasma
cell (PC), clone that produces toxic light chains (LC) that cause organ dysfunction and …